| *Disseminated on Behalf of Cardiol Therapeutics Inc.
Now Trending Green, (Nasdaq: CRDL) Continues Its Hold On My Top Watchlist Spot
August 22nd Greetings, Friend!
Cardiol Therapeutics Inc. (Nasdaq: CRDL) just pushed green and is currently sitting atop our watchlist.
Making a run of approx. 51% from a $.93+ low on August 8th to a high of $1.41+ on August 15th, CRDL's chart demonstrated its volatile potential.
And with CRDL maintaining above key $1.00 psychological resistance since August 12th, it's hard not wanting to consider this Nasdaq idea for a spot on your radar.
Could support be growing at that $1.00 level?
With multiple analyst targets pointing to triple-digit upside potential, CRDL may be undervalued from its current chart positioning.
Take a moment to review my initial (Nasdaq: CRDL) report below and consider it for your radar. -----
Critical progress is being made in cardiovascular medicine, with a strong emphasis on therapies that address inflammatory heart conditions—areas where few treatments currently exist despite significant patient need.
Research efforts targeting diseases such as pericarditis and myocarditis are beginning to show encouraging results, as clinical programs move closer to providing potential new options for those affected by these challenging conditions.
Driving this work is a dedicated life sciences company, led by seasoned experts and united by a clear focus on tackling some of the most urgent issues in cardiac health.
With new initiatives underway in fields like heart failure, the achievements of this team could start gaining increased attention across the medical community—highlighting a story that matters to anyone watching meaningful change in hea.lthcare.
And with topline results dropping recently and multiple analyst targets pointing to triple-digit potential upside, this under-the-radar Nasdaq profile has risen quickly to the top of my watchlist.
Consider checking out:
*Cardiol Therapeutics Inc. (Nasdaq: CRDL)*
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
And based on several potential catalysts, (Nasdaq: CRDL) takes over Monday's watchlist's top spot. Check them out:
#1. Advancing Therapies That Target Inflammation In The Heart!
#2. Cardiol Therapeutics Enrolling Patients In A Pivotal Phase III MAVERIC Trial.
#3. Cardiol Therapeutics Announced Phase II Topline Results.
#4. Multiple Analyst Targets Point To Triple-Digit Potential Upside!
But more on those in a second...
Cardiol's Immediate Focus
The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.
Pericarditis
Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States; following an initial episode, 15 – 30% of patients experience a recurrence.
Pericarditis refers to inflammation of the membrane or sac that surrounds the heart (the pericardium) that is most frequently triggered from a viral infection. Recurrent pericarditis is the most common complication following an initial acute episode of pericarditis, and patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Infrequent but life-threatening complications associated with pericarditis include a large accumulation of pericardial fluid, scarring, and constriction of the heart which may limit heart function. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.
Cardiol’s MAVERIC program for recurrent pericarditis has two parts. The first, a Phase II study, is already completed. The second, a larger pivotal Phase III trial, is still enrolling patients. This global study will show if CardiolRx™ can stop the disease from coming back in high-risk patients and help get it approved by regulators. -----
Myocarditis
Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is when the heart muscle gets inflamed. It can cause chest pain, trouble with how the heart works, and abnormal heart rhythms. In some cases, it can lead to severe heart failure or even sudden death, especially in people under 35.
Most often, it’s caused by a vi-rus, but it can also come from bacteria, certain medications, mRNA vaccines, or cancer treatments like chemotherapy and immune- based drugs.
CardiolRx™ was tested in the ARCHER trial, a Phase II study which took place in the US, Canada, Brazil, France, and Israel. The goal was to see if the drug is safe, well tolerated, and helps the heart recover in people with acute myocarditis. The topline results were just announced! -----
Heart Failure
Heart failure affects more than 64 million people globally and associated heal.thcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is when the heart can’t pump enough blood and oxygen for the body. This can cause shortness of breath, a fast heartbeat, swelling, low energy, and trouble doing everyday activities. Many people with heart failure end up in the hospital often, and it can greatly affect quality of life.
It can be caused by heart attacks, high blood pressure, heart valve problems, heart inflammation (like myocarditis), certain cancer treatments, or inherited conditions.
CRD-38 is Cardiol’s new subcutaneously administered drug formulation for heart failure. They’re doing the prep work needed before starting clinical trials to see if it can become a new treatment option. -----
Product Pipeline | 
0 التعليقات:
إرسال تعليق